Skip to content
BiologicalX

Comparison

N-Acetyl Cysteine vs Thymosin Alpha-1

Side-by-side of N-Acetyl Cysteine and Thymosin Alpha-1. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

N-Acetyl Cysteine

  • Replenishes intracellular glutathione by supplying cysteine, the rate-limiting amino acid for synthesis
  • First-line antidote for acetaminophen toxicity, restoring hepatic glutathione before fulminant injury occurs
  • Reduces sputum viscosity in chronic bronchitis and COPD at 600 to 1200 mg/day over months
  • Modest symptom reductions in OCD and trichotillomania at 1200 to 2400 mg/day across small RCTs
  • Mixed evidence for psychiatric adjunct use in bipolar depression and schizophrenia negative symptoms
  • Inhaled forms can trigger bronchospasm in active asthma; oral use is the standard biohacker route

Thymosin Alpha-1

  • 28-amino-acid synthetic peptide identical to thymic-derived immunomodulator
  • Approved in over 35 countries as Zadaxin for hepatitis B, hepatitis C adjunct, and immune support
  • Not FDA approved in US; compounded by 503A/503B pharmacies for off-label immune support
  • Modulates T-cell maturation, NK activity, and Th1 polarization in immunocompromised states
  • Standard label dose: 1.6 mg subcutaneously twice weekly
  • Cleanest safety profile in the peptide class with hundreds of regulated trials behind it

Side-by-side

Attribute N-Acetyl Cysteine Thymosin Alpha-1
Category supplement peptide
Also known as NAC Talpha1, Ta1, Zadaxin, Thymalfasin
Half-life (hr) 5.6 2
Typical dose (mg) 1200 1.6
Dosing frequency 1 to 3 times daily, split dosing preferred 2x weekly
Routes oral, iv subcutaneous, intramuscular
Onset (hr) 1 24
Peak (hr) 2 168
Molecular weight 163.19 3108.32
Molecular formula C5H9NO3S C129H215N33O55
Mechanism Deacetylated to cysteine, the rate-limiting precursor for glutathione synthesis; also directly scavenges reactive oxygen species and modulates glutamate signaling. Synthetic peptide modulator of innate and adaptive immunity. Promotes T-cell maturation and CD4/CD8 production, modulates Th1/Th2 balance, stimulates NK cell activity, and modulates TLR2/TLR9 signaling in dendritic cells.
Legal status OTC in most jurisdictions; restricted periods in US history (FDA reclassified 2022) Approved in 35+ countries as Zadaxin (hepatitis B, hepatitis C adjunct, immune support); not FDA approved in US; compounded by 503A/503B pharmacies for off-label use; not on WADA Prohibited List
WADA status allowed unknown
DEA / Rx OTC supplement (US, post-2022); Rx indications also exist (acetaminophen overdose, mucolytic) Rx only via international approval or US compounding (no controlled-substance schedule)
Pregnancy Used clinically in pregnancy for specific indications; consult clinician Not recommended; insufficient data
CAS 616-91-1 62304-98-7
PubChem CID 12035 16130571
Wikidata Q413299 Q913854

Safety profile

N-Acetyl Cysteine

Common side effects

  • sulfur-like taste or odor
  • nausea
  • flatulence
  • diarrhea

Contraindications

  • active asthma attack (inhaled form can trigger bronchospasm)
  • known NAC hypersensitivity

Interactions

  • nitroglycerin: potentiates vasodilation, risk of hypotension and headache(moderate)
  • activated charcoal: reduces NAC absorption when used for acetaminophen overdose(moderate)
  • anticoagulants: theoretical additive antiplatelet effect at high doses(minor)

Thymosin Alpha-1

Common side effects

  • mild injection-site irritation (rare)
  • transient mild fatigue (rare)
  • occasional headache (rare)

Contraindications

  • pregnancy
  • lactation
  • active organ transplant rejection therapy
  • systemic immunosuppression for autoimmune disease (relative)
  • severe active autoimmune disease (caution)

Interactions

  • interferon-alpha: additive immune effect; used clinically in approved combination protocols(minor)
  • calcineurin inhibitors (cyclosporine, tacrolimus): theoretical destabilization of immunosuppression; avoid(major)
  • antimetabolites (azathioprine, mycophenolate): theoretical destabilization of immunosuppression; avoid(major)
  • vaccine administration: may augment vaccine response in elderly or immunocompromised; coordinate with clinician(minor)

Which Should You Take?

N-Acetyl Cysteine comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC, oral dosing, with a Tier-A outcome catalogued. Thymosin Alpha-1 is the right call when one of the conditionals below applies.

Edge case: If you want to avoid Approved in 35+ countries as Zadaxin (hepatitis B, hepatitis C adjunct, immune support); not FDA approved in US; compounded by 503A/503B pharmacies for off-label use; not on WADA Prohibited List, N-Acetyl Cysteine is the more accessible choice.

Default choice: N-Acetyl Cysteine. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Thymosin Alpha-1 only if your priority sits squarely in the goals it owns above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between N-Acetyl Cysteine and Thymosin Alpha-1?

N-Acetyl Cysteine and Thymosin Alpha-1 differ in category (supplement vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, N-Acetyl Cysteine or Thymosin Alpha-1?

N-Acetyl Cysteine half-life is 5.6 hours; Thymosin Alpha-1 half-life is 2 hours.

Can you stack N-Acetyl Cysteine with Thymosin Alpha-1?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper